Zevra Therapeutics Inc. share price logo

Zevra Therapeutics Inc. Share Price

NASDAQ: ZVRA

Small Cap

$10.68

+0.28

(+2.69%)

as on

Zevra Therapeutics Inc. Stock Performance

as on April 18, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $10.62
    $10.95
    downward going graph

    0.56%

    Downside

    2.53%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $6.85
    $13.16
    downward going graph

    35.86%

    Downside

    23.22%

    Upside

    downward going graph

Zevra Therapeutics Inc. share price movements today

Previous Close
$10.40
Open
$10.69
Volume
1.4M
Day's Low - High
$10.62 - $10.95
52 Week Low - High
$6.85 - $13.16

Zevra Therapeutics Inc. Historical Returns

1 Month Return
+ 5.05 %
3 Month Return
+ 16.46 %
1 Year Return
+ 45.45 %
3 Year Return
+ 66.93 %
5 Year Return
0 %

Zevra Therapeutics Inc. Stock Fundamentals & Key Indicators

Check Zevra Therapeutics Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$610.6M

EPS (TTM)

0.4963

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

7.7

Industry PE ratio

-3.093115577889447

PEG Ratio

10.6667

EBITDA

-179.0K

Revenue (TTM)

106.5M

Profit Margin

78.17%

Return On Equity TTM

85.66%

Zevra Therapeutics Inc. Stock Valuation

Track how Zevra Therapeutics Inc. P/E has moved over time to understand its valuation trends.

Zevra Therapeutics Inc. in the last 5 years

  • Overview

  • Trends

Lowest (-12.23x)

September 30, 2025

Industry (-3.09x)

April 17, 2026

Today (7.70x)

April 17, 2026

Highest (157.62x)

December 31, 2025

LowHigh

Today’s Price to Earnings Ratio: 7.70x

Zevra Therapeutics Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Zevra Therapeutics Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Zevra Therapeutics Inc. image
Zevra Therapeutics Inc.
BUY$610.6MNA7.778.17%
Alnylam Pharmaceuticals Inc image
Alnylam Pharmaceuticals Inc
BUY$42.7B130.51%136.818.45%
Vertex Pharmaceuticals Inc image
Vertex Pharmaceuticals Inc
BUY$110.8B98.57%28.4232.94%
BeiGene, Ltd. image
BeiGene, Ltd.
NA$36.8BNA129.845.37%
Regeneron Pharmaceuticals Inc image
Regeneron Pharmaceuticals Inc
BUY$78.9B48.43%17.9831.41%

Stock Returns calculator for Zevra Therapeutics Inc. Stock including INR - Dollar returns

The Zevra Therapeutics Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

Zevra Therapeutics Inc. investment value today

Current value as on today

₹1,62,277

Returns

₹62,277

(+62.28%)

Returns from Zevra Therapeutics Inc. Stock

₹49,371 (+49.37%)

Dollar Impact

₹12,906 (+12.91%)

Analyst Recommendation on Zevra Therapeutics Inc. Stock

Based on 12 analysts

BUY

91.67%

Buy

8.33%

Hold

0.00%

Sell

Based on 12 analysts, 91.67% of analysts recommend a 'BUY' rating for Zevra Therapeutics Inc.. Average target price of $22.78

Zevra Therapeutics Inc. Share Price Target

Get share price movements and forecasts by analysts on Zevra Therapeutics Inc..

What analysts predicted

53.12%UPSIDE

Target Price

$22.78

Current Price

$10.68

Analyzed by

12 Analysts

Target

$22.78

Zevra Therapeutics Inc. target price $22.78, a slight upside of 53.12% compared to current price of $10.68. According to 12 analysts rating.

Zevra Therapeutics Inc. Stock’s Investor Sentiment and Interest

Search interest for Zevra Therapeutics Inc. Stock has decreased by -76% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-76% versus previous 30 day period

Zevra Therapeutics Inc. Quarterly Profit & Loss

All numbers in Millions USD

Jun 2023
Sep 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
8
2
3
4
3
12
20
25
26
34
Gross Profit
7
2
0
0
1
10
19
13
24
32
Operating Income
-6
-15
-20
-23
-27
-15
-5
-71
4
9
EBITDA
-2
-13
-14
-16
-29
-16
1
80
1
14
Interest Expense
0
0
0
2
2
2
1
2
2
1
Depreciation
0
0
1
1
1
1
1
1
0
0
Income Before Tax
-2
-10
-16
-19
-33
-20
-1
76
0
12
Income Tax Expense
0
0
0
0
-
15
1
2
0
0
Net Income
-2
-10
-16
-19
-33
-35
-3
74
0
12
Net Profit Margin
-30.38%
-358.10%
-485.31%
-447.85%
-899.19%
-296.76%
-15.19%
288.66%
-2.09%
35.65%

Zevra Therapeutics Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
12
13
28
10
27
23
106
Gross Profit
9
11
26
9
24
16
89
Operating Income
-20
-5
7
-42
-49
-87
-4
EBITDA
-17
-5
-7
-25
-43
-76
98
Interest Expense
6
7
0
0
1
7
7
Depreciation
0
0
0
0
0
6
4
Income Before Tax
-24
-12
-8
-26
-46
-90
86
Income Tax Expense
0
0
0
0
-
15
3
Net Income
-24
-12
-8
-26
-46
-105
83
Net Profit Margin
-191.00%
-96.03%
-29.86%
-263.48%
-167.69%
-446.85%
78.17%

Zevra Therapeutics Inc. Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-15
-16
-19
-33
-35
-3
74
0
12
Operating Cash Flow
-16
-16
-19
-18
-16
-8
-3
4
5
Investing Cash Flow
-
14
0
-31
-5
10
11
-4
0
Financing Cash Flow
5
1
15
64
0
1
1
6
2
Change in Cash
0
0
-3
14
-20
3
10
6
7

Zevra Therapeutics Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-43
-56
-24
-12
-8
-41
-46
-105
83
Operating Cash Flow
-33
-54
-23
-1
10
-18
-33
-69
-1
Investing Cash Flow
27
33
3
0
-15
-36
-17
-22
18
Financing Cash Flow
0
28
4
2
113
8
28
82
12
Change in Cash
-5
7
-15
0
108
-46
-22
-9
28

Zevra Therapeutics Inc. News & Key Events

  • img

    Today's Timeline - 10 March

    Tue, 02:12 PM

    -

    Zevra Therapeutics reports earnings of 19 cents, beating estimates, with sales of $34.1 million, boosting shares by 17.2%.

Insights on Zevra Therapeutics Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, ZVRA has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, ZVRA has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 6 quarters, 3.69M → 34.12M (in $), with an average increase of 31.2% per quarter

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -544.0K → 12.16M (in $), with an average increase of 104.5% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, ZVRA stock has moved up by 9.8%

About Zevra Therapeutics Inc.

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. The company was incorporated in 2006 and is headquartered in Boston, Massachusetts.
OrganisationZevra Therapeutics Inc.
Headquarters101 Federal Street, Boston, MA, United States, 02110
IndustryBiotechnology
CEOMr. Neil F. McFarlane
E-voting on sharesClick here to vote

Key Management of Zevra Therapeutics Inc.

Name

Title

Mr. Gerald J. Orehostky

Senior Vice President of Regulatory Affairs & Quality

Ms. Alison Peters

Chief People Officer

Mr. Joshua M. Schafer M.B.A.

Chief Commercial Officer

Mr. Justin A. Renz CPA, MBA

CFO & Treasurer

Ms. Nichol L. Ochsner

Vice President of Investor Relations & Corporate Communications

Mr. Rahsaan W. Thompson J.D.

Chief Legal Officer, Secretary & Compliance Officer

Dr. Christopher M. Lauderback Ph.D.

Senior Vice President of Manufacturing

Ms. Tanya Hayden

Senior VP & Chief of Staff

Mr. Neil F. McFarlane

President, CEO & Director

Dr. Adrian Quartel FFPM, M.D.

Chief Medical Officer

FAQs

What is Zevra Therapeutics Inc. share price today?

Zevra Therapeutics Inc. share price today is $10.68 as on at the close of the market. Zevra Therapeutics Inc. share today touched a day high of $10.95 and a low of $10.62.

What is the 52 week high and 52 week low for Zevra Therapeutics Inc. share?

Zevra Therapeutics Inc. share touched a 52 week high of $13.16 on and a 52 week low of $6.85 on . Zevra Therapeutics Inc. stock price today i.e. is closed at $10.68,which is 18.84% down from its 52 week high and 55.91% up from its 52 week low.

What is Zevra Therapeutics Inc.'s market capitalisation today?

Zevra Therapeutics Inc. market capitalisation is $0.00T as on .

How to invest in Zevra Therapeutics Inc. Stock (ZVRA) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Zevra Therapeutics Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Zevra Therapeutics Inc. Shares that will get you 0.1404 shares as per Zevra Therapeutics Inc. share price of $10.68 per share as on April 18, 2026 at 1:29 am IST.

What is the minimum amount required to buy Zevra Therapeutics Inc. Stock (ZVRA) from India?

Indian investors can start investing in Zevra Therapeutics Inc. (ZVRA) shares with as little as ₹92.768 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹927.68 in Zevra Therapeutics Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Zevra Therapeutics Inc. share’s latest price of $10.68 as on April 18, 2026 at 1:29 am IST, you will get 0.9363 shares of Zevra Therapeutics Inc.. Learn more about fractional shares .